logo
ResearchBunny Logo
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs

Medicine and Health

Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs

R. Capuano, L. Prosperini, et al.

This study investigated the impact of a third mRNA vaccine dose on COVID-19 outcomes in multiple sclerosis patients treated with ocrelizumab, fingolimod, and natalizumab. The research, conducted by Rocco Capuano and colleagues, found that while some differences in COVID-19 symptoms and hospitalization rates existed among treatments, no deaths occurred, and the booster dose showed effectiveness against severe COVID-19.

00:00
00:00
Playback language: English
Abstract
This study evaluated COVID-19 course and outcomes in multiple sclerosis (MS) patients treated with ocrelizumab (OCR), fingolimod (FNG), or natalizumab (NTZ) after a third mRNA vaccine dose. 290 patients from 17 Italian MS centers were included. While those on OCR and FNG showed slightly more symptomatic COVID-19 and higher hospitalization rates than those on NTZ, regression models indicated that most differences weren't due to DMTs. No deaths occurred. The study supports the third booster dose's effectiveness against severe COVID-19 in MS patients on OCR and FNG.
Publisher
Multiple Sclerosis Journal
Published On
Mar 29, 2023
Authors
Rocco Capuano, Luca Prosperini, Manuela Altieri, Lorena Lorefice, Roberta Fantozzi, Paola Cavalla, Clara Guaschino, Marta Radaelli, Cinzia Cordioli, Viviana Nociti, Laura Boffa, Paolo Ragonese, Maria Di Gregorio, Federica Pinardi, Valentina Torri Clerici, Giovanna De Luca, Alberto Gajofatto, Damiano Paolicelli, Carla Tortorella, Claudio Gasperini, Claudio Solaro, Eleonora Cocco, Alvino Bisecco, Antonio Gallo, Giovanni Di Dio
Tags
COVID-19
multiple sclerosis
ocrelizumab
fingolimod
natalizumab
vaccine effectiveness
hospitalization rates

Related Publications

Explore these studies to deepen your understanding of the subject.

Severe T cell hyporeactivity in ventilated COVID-19 patients correlates with prolonged virus persistence and poor outcomes
Medicine and Health

Severe T cell hyporeactivity in ventilated COVID-19 patients correlates with prolonged virus persistence and poor outcomes

K. Renner, T. Schiwitty, et al.

Three-year outcomes and predictors for full recovery in patients with early-stage psychosis
Psychology

Three-year outcomes and predictors for full recovery in patients with early-stage psychosis

L. Li, F. Z. Rami, et al.

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study
Medicine and Health

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study

J. An, X. Li, et al.

COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition
Medicine and Health

COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition

S. Zhao, K. Y. W. Lok, et al.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny